Display options
Cite
Jensen L, Yuh B, Wong JYC, et al. Outcomes and toxicity of 313 prostate cancer patients receiving helical tomotherapy after radical prostatectomy. Adv Radiat Oncol. 2017;2(4):597-607doi: 10.1016/j.adro.2017.08.004.
Jensen, L., Yuh, B., Wong, J. Y. C., Schultheiss, T., Cheng, J., Ruel, N., Twardowski, P., & Sampath, S. (2017). Outcomes and toxicity of 313 prostate cancer patients receiving helical tomotherapy after radical prostatectomy. Advances in radiation oncology, 2(4), 597-607. https://doi.org/10.1016/j.adro.2017.08.004
Jensen, Lindsay, et al. "Outcomes and toxicity of 313 prostate cancer patients receiving helical tomotherapy after radical prostatectomy." Advances in radiation oncology vol. 2,4 (2017): 597-607. doi: https://doi.org/10.1016/j.adro.2017.08.004
Jensen L, Yuh B, Wong JYC, Schultheiss T, Cheng J, Ruel N, Twardowski P, Sampath S. Outcomes and toxicity of 313 prostate cancer patients receiving helical tomotherapy after radical prostatectomy. Adv Radiat Oncol. 2017 Aug 08;2(4):597-607. doi: 10.1016/j.adro.2017.08.004. eCollection 2017. PMID: 29204527; PMCID: PMC5707427.
Copy Download .nbib Format: NLM
Share it on

Adv Radiat Oncol. 2017 Aug 08;2(4):597-607. doi: 10.1016/j.adro.2017.08.004. eCollection 2017.

Outcomes and toxicity of 313 prostate cancer patients receiving helical tomotherapy after radical prostatectomy.

Advances in radiation oncology

Lindsay Jensen, Bertram Yuh, Jeffrey Y C Wong, Timothy Schultheiss, Jonathan Cheng, Nora Ruel, Przemyslaw Twardowski, Sagus Sampath

Affiliations

  1. Department of Radiation Oncology, City of Hope National Medical Center, Duarte, California.
  2. Department of Urology, City of Hope National Medical Center, Duarte, California.
  3. Altus Cancer Center, Baytown, Texas.
  4. Department of Biostatistics, City of Hope National Medical Center, Duarte, California.
  5. Department of Radiation Oncology, City of Hope Medical Center, Duarte, California.

PMID: 29204527 PMCID: PMC5707427 DOI: 10.1016/j.adro.2017.08.004

Abstract

PURPOSE: There are limited long-term data on patients treated with image guided intensity modulated radiation therapy (IG-IMRT) for prostate cancer recurrence or high-risk disease features after radical prostatectomy. We report single-institution results for patients treated with IG-IMRT and identify variables associated with outcome.

METHODS AND MATERIALS: This is a retrospective chart review consisting of 313 consecutive patients who were treated with adjuvant or salvage IG-IMRT from 2004 to 2013. Cox proportional hazards analysis was used to identify factors related to survival and toxicity. Toxicity was graded using the Common Terminology Criteria for Adverse Events Version 4.0.

RESULTS: The median follow-up was 55 months (range, 6-131 months). The median pre-radiation therapy (RT) prostate-specific antigen (PSA) was 0.3 ng/mL (range, <0.01-55.4). The vast majority of patients (87%) received elective pelvic nodal irradiation (median dose: 45 Gy). Androgen deprivation therapy (ADT) was given to 39% of patients for a median of 9 months. Five-year biochemical progression-free survival and distant metastasis-free survival were 59% (95% confidence interval, 53%-66%) and 89% (95% confidence interval, 85%-93%), respectively. On multivariate analysis, higher pre-RT PSA (>0.2 ng/mL), biopsy Gleason score (≥7 [4+3]), and duration of ADT (>6 months) were significantly associated (

CONCLUSION: Our results suggest that lower pre-RT PSA level and longer duration of ADT are associated with improved biochemical control. The incidence of late grade 3 gastrointestinal toxicity was low, but late grade 3 genitourinary toxicity was higher than anticipated.

References

  1. JAMA. 2008 Jun 18;299(23):2760-9 - PubMed
  2. Int J Radiat Oncol Biol Phys. 2010 Oct 1;78(2):435-41 - PubMed
  3. Radiother Oncol. 2008 Nov;89(2):205-13 - PubMed
  4. J Urol. 1995 Jul;154(1):131-8 - PubMed
  5. Med Dosim. 2011 Autumn;36(3):264-71 - PubMed
  6. Eur Urol. 2014 Aug;66(2):243-50 - PubMed
  7. J Urol. 2017 Mar;197(3 Pt 1):662-668 - PubMed
  8. J Clin Oncol. 2007 May 20;25(15):2035-41 - PubMed
  9. Eur Urol. 2009 Oct;56(4):669-75 - PubMed
  10. Int J Radiat Oncol Biol Phys. 2010 Feb 1;76(2):361-8 - PubMed
  11. Acta Oncol. 2015 Jun;54(6):854-61 - PubMed
  12. N Engl J Med. 2017 Feb 2;376(5):417-428 - PubMed
  13. Eur Urol. 2011 Oct;60(4):842-9 - PubMed
  14. JAMA Intern Med. 2013 Jun 24;173(12):1136-43 - PubMed
  15. Am J Clin Oncol. 2015 Feb;38(1):55-60 - PubMed
  16. Int J Radiat Oncol Biol Phys. 2012 Sep 1;84(1):104-11 - PubMed
  17. J Urol. 2006 Dec;176(6 Pt 1):2453-8; discussion 2458 - PubMed
  18. Pract Radiat Oncol. 2015 Sep-Oct;5(5):e473-82 - PubMed
  19. Int J Radiat Oncol Biol Phys. 2013 Feb 1;85(2):549-54 - PubMed
  20. J Urol. 2005 Jun;173(6):2099-103 - PubMed
  21. Int J Oncol. 2013 Jan;42(1):109-17 - PubMed
  22. Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):191-9 - PubMed
  23. J Cancer Res Ther. 2014 Jul-Sep;10(3):575-82 - PubMed
  24. J Urol. 2009 Mar;181(3):956-62 - PubMed
  25. J Urol. 2013 Feb;189(2):602-8 - PubMed
  26. Lancet. 2012 Dec 8;380(9858):2018-27 - PubMed
  27. Eur Urol. 2008 Apr;53(4):767-75; discussion 775-6 - PubMed
  28. Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):351-7 - PubMed
  29. Eur Urol. 2015 Feb;67(2):273-80 - PubMed
  30. J Clin Oncol. 2005 Oct 1;23(28):7005-12 - PubMed
  31. Eur Urol. 2011 Dec;60(6):1142-8 - PubMed
  32. Lancet Oncol. 2016 Jun;17 (6):747-756 - PubMed
  33. Radiother Oncol. 2009 Nov;93(2):226-33 - PubMed

Publication Types

Grant support